GliaCure Launches First-in-Human Study for Alzheimer’s Disease

GliaCure Launches First-in-Human Study for Alzheimer’s Disease
A Boston-based private biotech company has revealed it has begun the first-in-human clinical trial for one of their leading pipeline products for Alzheimer’s disease — the most common form of dementia that affects over 5 million Americans today, and is the cause of more than 500,000 deaths among older adults every year. GliaCure, true to their specialization

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *